Stockscreener 앱 받기
4.71
2.08%
-0.10
시간 외 거래:
4.60
-0.11
-2.34%
전일 마감가:
$4.81
열려 있는:
$4.8
하루 거래량:
93,114
Relative Volume:
0.63
시가총액:
$110.48M
수익:
$7.95M
순이익/손실:
$-21.23M
주가수익비율:
-3.9234
EPS:
-1.2005
순현금흐름:
$-11.90M
1주 성능:
+3.06%
1개월 성능:
+9.03%
6개월 성능:
-26.18%
1년 성능:
-20.17%
1일 변동 폭
$4.625
$4.83
1주일 범위
$4.50
$5.0076
52주 변동 폭
$3.7101
$7.75
Coya Therapeutics Inc Stock (COYA) Company Profile
명칭
Coya Therapeutics Inc
전화
650.739.3939
주소
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON
Compare COYA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
COYA
Coya Therapeutics Inc
|
4.71 | 112.83M | 7.95M | -21.23M | -11.90M | -1.2005 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Coya Therapeutics Inc Stock (COYA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-09 | 개시 | Lake Street | Buy |
| 2024-12-04 | 개시 | D. Boral Capital | Buy |
Coya Therapeutics Inc 주식(COYA)의 최신 뉴스
COYA | Coya Therapeutics, Inc. Common Executive Compensation - Quiver Quantitative
Coya Therapeutics secures FDA fast track status for COYA 302 - Yahoo Finance
Analysts Are Bullish on These Healthcare Stocks: BridgeBio Pharma (BBIO), Palisade Bio (PALI) - The Globe and Mail
Lake Street Maintains Coya Therapeutics(COYA.US) With Buy Rating, Maintains Target Price $17 - Moomoo
8-K: Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Updatemoomoo - Moomoo
H.C. Wainwright Maintains Coya Therapeutics(COYA.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Chardan Capital Maintains Coya Therapeutics(COYA.US) With Buy Rating, Maintains Target Price $14 - Moomoo
FDA puts injection therapy COYA 302 on fast track for treating ALS - ALS News Today
[ARS] Coya Therapeutics, Inc. SEC Filing - Stock Titan
Coya Therapeutics (COYA) 2026 proxy outlines director elections and auditor ratification - Stock Titan
Coya Therapeutics 1Q Research and Development Expenses $4.1 M >COYA - Moomoo
FDA Fast Track Designation Boosts ALS Treatment Outlook; Analyst Sees More Than 250% Upside Potential - Streetwise Reports
Coya Therapeutics Announces $30 Million At-the-Market Offering Agreement with Leerink Partners - Minichart
Coya Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Coya Therapeutics, Inc. Q1 2026 10-Q Filing: Financial Statements, Market Risks, and Legal Disclosures - Minichart
Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of - pharmiweb.com
Coya Therapeutics Establishes $30 Million ATM Equity Program - TipRanks
Coya Therapeutics entered into sales agreement, may offer and sell from time to time shares of co's common stock for up to $30 million - marketscreener.com
Coya Therapeutics Entered Into Sales Agreement, May Offer And Sell From Time To Time Shares Of Co's Common Stock For Up To $30 Million - TradingView
Coya Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Coya Therapeutics Updates Q1 Results, COYA 302 Progress - TipRanks
Coya Therapeutics (COYA) launches $30,000,000 at-the-market stock offering - Stock Titan
Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) - BioSpace
Coya Therapeutics (COYA) launches $30M at‑the‑market equity program with Leerink - Stock Titan
Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update - BioSpace
Coya Therapeutics receives FDA fast track for ALS treatment By Investing.com - Investing.com Australia
Coya Therapeutics Reports Q1 2026 Financial Results, Highlights ALS and FTD Drug Progress and FDA Fast Track Designation - Minichart
Coya Therapeutics receives FDA fast track for ALS treatment - Investing.com
Coya Therapeutics, Inc. 1Q 2026: Revenue $0.25M, EPS $(0.32) — 10-Q Summary - TradingView
Coya Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Coya Therapeutics (NASDAQ: COYA) posts Q1 loss as COYA 302 wins FDA Fast Track - Stock Titan
Fast Track lifts Coya Therapeutics (NASDAQ: COYA) Q1 2026 biotech update - Stock Titan
TradingKey - TradingKey
Coya Therapeutics Inc expected to post a loss of 41 cents a shareEarnings Preview - TradingView
Why Coya (COYA) is still under the radar (Touches Low) 2026-05-07Oversold Bounce - Newser
Coya Therapeutics (COYA) Expected to Announce Earnings on Tuesday - MarketBeat
ALS Researchers Use Stratification, Diverse Endpoints To Address Heterogeneity - Clinical Leader
Coya Therapeutics raises $11.1M in private placement led by Dr. Reddy's - MSN
Analysts Offer Insights on Healthcare Companies: Monopar Therapeutics Inc (MNPR), ClearPoint Neuro (CLPT) and CG Oncology, Inc. (CGON) - The Globe and Mail
Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Coya Therapeutics (NASDAQ:COYA) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Mark H Pavao Net Worth (2026) - GuruFocus
COYA Options Volatility — NASDAQ:COYA - TradingView
COYA Options Chain — NASDAQ:COYA - TradingView
Is Coya (COYA) Stock Safe to Buy Now | COYA Q4 Earnings: Misses Estimates by $0.06Expert Breakout Alerts - Newser
COYA PE Ratio & Valuation, Is COYA Overvalued - Intellectia AI
COYA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Volume Report: Is Coya Therapeutics Inc impacted by rising ratesTrade Analysis Report & High Accuracy Trade Alerts - baoquankhu1.vn
Coya Therapeutics Is Maintained at Buy by D. Boral Capital - Moomoo
Coya Therapeutics' (COYA) Buy Rating Reiterated at D. Boral Capital - MarketBeat
Market Review: Is Coya Therapeutics Inc benefiting from innovation trends2026 Catalysts & Accurate Entry/Exit Alerts - baoquankhu1.vn
Coya Therapeutics Inc (COYA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.12%
자본화:
|
볼륨(24시간):